November 16th, 2023

Life Sciences BC seeks to raise the profile of our members and supporters, highlight their achievements, and promote BC's dynamic life sciences ecosystem. If you have news or a story to share, let us know. You can find previous editions of BioLinks newsletters and other resources on our website at News/Publications.

I had the pleasure of attending the Greater Vancouver Board of Trade event this week, where The Honourable François-Philippe Champagne, Canada's federal Minister of Innovation, Science, and Industry, engaged in a thought-provoking discussion and shared insights on critical subjects such as talent, the significant role of anchor companies, and British Columbia's attractiveness as a talent hub. He spoke about cutting-edge AI, cybersecurity, and quantum computing advancements, emphasizing the importance of ambitiously leveraging our strengths and capabilities to adapt and thrive in the swiftly evolving global landscape. Congratulations to the GVBOT for hosting a great event!

This week, we are pleased to launch BioBasics 201: Targeted Biologics for the Non-Scientist, the sequel to BioBasics 101. This 2-day course in January is ideal for non-scientists with foundational knowledge in DNA, RNA, proteins, and cell signaling who wish to enhance their understanding of biotech principles to enable more informed discussions with colleagues.

Limited spots also remain for the upcoming BioBasics 101, taking place later this month, which provides a foundational understanding of the science underpinning biopharma.

We are excited to attend the J.P. Morgan Conference in January! If you're a BC company attending, let us know here so we can coordinate efforts. You also won’t want to miss our upcoming Blakes Breakfast Speaking Series: Preparing for J.P. Morgan Week on Dec. 13! Christian Barrow of J.P. Morgan, Ali Ardakani of Novateur Ventures, our Board Chair, and Allison Gaw of Amplitude Ventures will provide valuable insights to enhance your conference experience. Learn more.

Member Highlights 

Approximately 10% of Canadians will experience significant depression during their lifetime, making it a significant public health challenge. A recent UBC research project, supported by Genome BC, Genome Canada, and Michael Smith Health Research BC and featured in CMAJ, explores utilizing genetic testing to tailor depression treatment. Learn more.

Dr. Jerry Silver of NervGen Pharma was recently featured on the Remarkable People podcast to discuss his work and the potential for neuroregeneration to treat spinal cord injuries. Listen here.

adMare BioInnovations has launched its adMare Community virtual network, where life sciences and biotech professionals can connect with corporate leaders, scientists, and emerging professionals. Learn more.

Jim Kean from Molecular You recently participated as a guest on the Ageless by Rescu podcast. The conversation explored the role of AI in advancing predictive healthcare and the ethical considerations it introduces. The discussion also emphasized the importance of a collaborative approach in fully unlocking the potential of AI in healthcare. Listen here.

New Member

NanoVation Therapeutics is an early-stage gene therapy company developing next-generation platform technologies utilizing lipid nanoparticles.

Prudential Cleanroom Services offers cleanroom solutions and services to facilities involved in the compounding and preparation of medications and sterile infusions.

Alliance Partners Development is a real estate developer, builder, and member of the community that creates distinctive, meaningful work spaces and commercial projects.

[Individual] Michael West joined IRAP in 2007, retiring in 2016. Post-retirement, he provided consulting services to Proteocyte and KMI. His expertise encompasses infectious diseases, cancer, inflammatory diseases, expression vectors, as well as protein and peptide biochemistry.  

Welcome all to the LSBC community!

Industry Highlights

BC's International Credentials Recognition Act achieved royal assent on Nov. 8. This exciting new legislation will streamline the entry of internationally trained professionals into the workforce. Covering 29 professions, including key roles in the life sciences sector, such as professional engineer, applied science technologist, professional biologist, applied biology technician, and registered biology technologist, the act paves the way for these professionals to work in their chosen field and address vital skills shortages. Expected to take effect in the summer of 2024, this act signifies a significant step toward enhancing inclusivity and efficiency in professional credential recognition. Learn more.

Those in Abbotsford, Kamloops, or Cranbrook are invited to learn how your business can benefit from BC’s and Canada’s free trade agreements and the export services available! Join the BC Ministry of Jobs, Economic Development and Innovation representatives and the Export Navigator Program on November 28 (Abbotsford), 30 (Kamloops) and Dec. 7 (Cranbrook) to learn more about accessing these opportunities and how they can benefit your business. Learn more.

Kudos

Kudos to PharmaAla Biotech, the first publicly traded company to produce GMP-certified, clinical-grade MDMA and the exclusive North American supplier, for being recognized as a top microcap value stock in a recent feature by Stockhouse. Learn more.

Congratulations to this year's 25th Vancouver ICD-Rotman Directors Education Program (DEP) graduates, including Tony Brooks of Genome BC and Deborah Mitchell of Providence Health Care! You can learn more about upcoming DEP offerings here.

I am honoured to have been included in this year's BIV BC 500 list recognized among the most influential business leaders in the Technology Leaders category. Sharing this distinction with esteemed leaders from the life sciences sector and LSBC members, such as Board Director Jennifer Cudlipp of LifeLabs, Hamed Shahbazi of WELL Health Technologies, and Haig Farris of Fractal Capital— both recent awardees at the LSBC Awards presented by Farris—is truly humbling. Additional honorees in this category from our member community include Sue Paish of Digital, Jill Tipping of BC Tech, and Handol Kim of Variational AI. It is a privilege to be part of such an accomplished group! For those interested, the complete list of honorees is available for BIV subscribers here. 

People on the Move

Brigitte Nolet, president and CEO of Roche Canada Pharma, has been selected as Innovative Medicines Canada's board of directors chair. Learn more. 

Mike Jeffries of Omega Laboratories has joined the Substance Abuse Program Administrators Association (SAPAA) Board of Directors. Learn more.

Vivian Wang of Nimbus Synergies has joined the Vancouver Entrepreneurs Forum Board of Directors. See the complete list of new board members here.

Applications Open

Health Canada is accepting applications to fund community-based support and evidence-based health intervention projects through its Substance Use and Addictions Program. Applications are due Nov. 22. Learn more.

The INOVAIT Canada Pilot Fund, supported by Canada’s Strategic Innovation Fund (SIF), seeks advanced projects that apply machine learning, artificial intelligence or big data in image-guided therapy. This opportunity is open to corporations, academic institutions, and not-for-profits, and projects must include 2-4 Canadian collaborators, with at least one SME and one collaborator outside Ontario. Applications are due Dec. 20. Learn more.

The Department of Health Research Methods, Evidence, and Impact at McMaster University is accepting applications for its Graduate Diploma in Clinical Epidemiology (GDCE) program. This online, part-time, course-based program covers core topics in clinical epidemiology. Applications are due Mar. 30, 2024, and the program will begin Sept. 3, 2024. Learn more here. 

Michael Smith Health Research BC is currently accepting applications for its Research Trainee 2024 competition, designed to support health researchers during their training phase via salary support for post-doctoral fellows and health professional researchers. The deadline to submit a LOI is Dec. 12, and an informational webinar is scheduled for Nov. 22. Learn more here.

We invite you to explore our expanded list of current life sciences application opportunities by clicking the button below.

Upcoming LSBC events and programs at-a-glance

NOV. 22 - Life Sciences BC is thrilled to announce our first LSBC Vancouver Island Winter Social in beautiful Victoria!

Nov. 29/30 - LSBC, in partnership with Biotech Primer, is pleased to present BioBasics 101: The Biology of Biotech for the Non-Scientist.

Dec. 13 - Attending J.P. Morgan Conference Week and need navigation tips? We invite you to join us for our Blakes Breakfast Speaking Series: Preparing for J.P. Morgan Week.

Dec. 14 - Join us alongside your industry colleagues for an evening of relaxed camaraderie as we toast the holiday season at the annual Life Sciences BC Holiday Party.

Jan. 16/17 - LSBC, in partnership with Biotech Primer, is pleased to present BioBasics 201: Targeted Biologics for the Non-Scientist.

We're thrilled to announce that we are one of the delivery partners for the new AccelerateIP (AIP) program, which helps startups leverage the potential of their IP.

Until next week,

Wendy and the LSBC team

Research Trainee 2024 Competition: Call for Applications

The Research Trainee program supports health researchers in the training phase of their research career to build capacity and contribute to the success of BC’s health research landscape. The award provides post-doctoral fellows or health professional researchers with salary support for dedicated research activities... READ MORE

Sustained Therapeutics Announces Clinical Trial of Second Product

Sustained Therapeutics (the “Company”) announced regulatory clearance for a pivotal Phase II/III human trial of its second product, a novel medication for the treatment of a rare form of cancer. Upper Tract Urethral Carcinoma (“UTUC”) is an orphan disease, a malignancy of the cells lining the renal pelvis. It affects about 6,000 patients each year in North America... READ MORE

Cytiva Transforms Protein Purification With Its New Affinity Technology That Works With Any Recombinant Protein

Cytiva, a global leader in life sciences, introduces the innovative Cytiva Protein Select technology, designed to streamline and accelerate recombinant protein purification. The self-cleaving traceless tag and complementary affinity chromatography resin standardizes purification for any protein, rendering it unnecessary to use specific affinity binding partners for each protein... READ MORE

New Process for Screening Old Urine Samples Reveals Previously Undetected ‘Designer Drugs’

In a study published today in Analytical Chemistry, they showed how high-resolution mass spectrometry can be used to analyze urine samples at scale and uncover molecules from emerging designer drugs that have been missed by conventional testing... READ MORE

Eupraxia Pharmaceuticals Reports Third Quarter 2023 Financial Results

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, announced its financial results (prepared in accordance with International Financial Reporting Standards) and operational highlights for the third quarter ended September 30, 2023. All amounts are expressed in Canadian dollars unless otherwise indicated... READ MORE

Filament Health and Nasdaq-Listed SPAC Jupiter Acquisition Corporation Announce Form F-4 Registration Statement Declared Effective By The U.S. Securities And Exchange Commission And Mailing of Definitive Proxy Statement

Filament Health Corp., a clinical‐stage natural psychedelic drug development company, and Jupiter Acquisition Corporation, a special purpose acquisition company (“SPAC”), announced that the U.S. Securities and Exchange Commission (the “SEC”) has declared effective the registration statement on Form F-4 filed with the SEC by 1427702 B.C. Ltd. (“TopCo”) related to the previously announced business combination among Filament, Jupiter and TopCo (the “Business Combination”)... READ MORE

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

 InMed Pharmaceuticals Inc., a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, reports financial results for the first quarter of the fiscal year 2024 which ended September 30, 2023. The Company’s full financial statements and related MD&A for the first quarter ended September 30, 2023, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov... READ MORE

Innovative Medicines Canada Welcomes Brigitte Nolet as New Board Chair

Innovative Medicines Canada (IMC) is pleased to announce that Brigitte Nolet, President and CEO of Roche Canada Pharma, has been selected as Chair of its Board of Directors.Brigitte, a Welland, Ontario native, has held a number of progressive leadership roles within Roche, locally and globally, since joining the company in 2006... READ MORE

Qu Biologics Receives Accelerating Clinical Trial (ACT) Funding for PERIOP-06 Clinical Trial

Qu Biologics Inc., is pleased to announce that its Phase 2 clinical trial in late-stage colon cancer, PERIOP-06, was awarded CAD$400,000 in grant funding by the Accelerating Clinical Trial (ACT) Canadian Consortium. ACT was founded in 2022 and is funded by the Canadian Institutes of Health Research (CIHR) Clinical Trials Fund to support clinical trials across Canada... READ MORE

Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) For Lupkynis® (Voclosporin) In Japan

Aurinia Pharmaceuticals Inc. announced that the Company’s collaboration partner, Otsuka Pharmaceutical Ltd., filed a new drug application (NDA) for voclosporin for the treatment of lupus nephritis (LN) with the Japanese Ministry of Health, Labour, and Welfare for the manufacture and sale in Japan of voclosporin, a second-generation oral calcineurin inhibitor for the treatment of lupus nephritis (LN)...READ MORE

The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis

Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, today announced findings from a descriptive analysis of a hospital database (October 2015-June 2022) showing that the absence of an overt hepatic encephalopathy-specific diagnosis code may have resulted in increased OHE-related length of stay (LOS) and hospitalization-related costs due to OHE rate underestimation... READ MORE

ACROBiosystems Launches the World’s First GMP-grade DLL-4 Protein

ACROBiosystems, a global cornerstone of the pharmaceutical industry committed to offering innovative tools and solutions, announces the launch of GMP grade DLL4. GMP grade DLL4 is the first recombinant Delta-like Ligand 4, or DLL4, to be launched on the market under GMP conditions... READ MORE

World’s First Observational Trial to Assess Real-World Efficacy of MDMA Treatment

PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) (OTC:PMBHF), the University of Calgary (“UC”), and Heroic Hearts Canada (“HHC”, and collectively, the “Parties”) are pleased to announce that they have completed a Letter of Intent (“LOI”), and received initial Ethics Board Approval, to initiate an Observational Trial (the “Trial”) on patients treated with 3,4 Methylenedioxymethamphetamine (“MDMA”) through Health Canada’s Special Access Program (SAP)... READ MORE

LifeLabs, Canada’s Leading Medical Laboratory, Expands to Trail B.C. with a Brand-New Location

LifeLabs, Canada’s leading provider of medical diagnostic services and recognized as the most trusted brand in health diagnostic services by Canadians, is thrilled to announce the upcoming grand opening of its new Patient Service Centre (PSC) in Trail, British Columbia... READ MORE

Neuroscientist And NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed On ‘Remarkable People’ Podcast Hosted By Tech Luminary Guy Kawasaki

Dr. Silver, Professor, Department of Neurosciences at Case Western Reserve University, has spent decades exploring ways to restore function for individuals with spinal cord injuries. He and his research team achieved an unprecedented breakthrough (Nature:13 July 2011) in spurring repair of the nervous system in preclinical models in the development of NVG-291. Dr. Silver’s technological discoveries were licensed to NervGen in 2018... READ MORE

Genevant Sciences to Collaborate with Novo Nordisk to Develop Gene Editing Treatment for Hemophilia A

Genevant Sciences, a leading nucleic acid delivery company with world- class platforms and an expansive lipid nanoparticle (LNP) patent portfolio, announced that it has entered into a collaboration and nonexclusive license agreement with Novo Nordisk to combine Genevant’s proprietary LNP technology with innovative mRNA-based megaTAL technology to develop an in vivo gene editing treatment for hemophilia A... READ MORE

Phyton Biotech is a leader in sustainable specialty fermentation solutions. As the largest global supplier of Plant Cell Fermentation (PCF®) -derived Paclitaxel & Docetaxel API – Phyton has transformed plant cell culture technology and developed a commercially scalable, reproducible, “green” (PCF®) process for the production of high-value phytochemicals. PCF® offers a time, risk and cost-balanced pathway to commercially viable production processes, overcoming limitations and drawbacks often experienced with traditional plant extraction and chemical synthesis.

Phyton Biotech offers comprehensive product/process development and commercial manufacturing services for high-value phytochemicals using our award-winning and environmentally responsible PCF® platform.

The company’s teams in Germany and Canada are uniquely qualified to carry out a full development program for plant-based molecules, extracts and recombinant products for use in a range of industries. Phyton Biotech is known globally for excellence, innovation, quality, reliability and cutting-edge technological solutions.

With the world‘s largest cGMP PCF® facility, and over 25 years of highly specialized experience in the development of customized process solutions and commercial production, Phyton Biotech is proud to collaborate with partners and clients in the Pharmaceutical, Herbal Traditional Chinese Medicine, Cosmetic, and Food Ingredient industries. LEARN MORE

Message from the Minister of Health – Diabetes Awareness Month and World Diabetes Day

Diabetes affects approximately 3.7 million people, with more than 200,000 new cases diagnosed every year, making it one of the most common chronic diseases in Canada. This Diabetes Awareness Month and World Diabetes Day, our government reaffirms its commitment to make meaningful change in the lives of those affected by diabetes... READ MORE

New Act Streamlines Credential Recognition for Internationally Trained Professionals

British Columbians will soon benefit from internationally trained professionals having an easier path to working in their chosen careers and filling crucial skills shortages as the International Credentials Recognition Act received royal assent on Nov. 8, 2023. The act will increase fairness, efficiency, transparency and accountability in the credential recognition process. It will require 18 regulatory bodies to remove barriers in 29 professions and make it easier and quicker for qualified professionals to seek credential recognition, regardless of where they were trained... READ MORE

Research Associate

Reporting to the Manager, and under the guidance of a research supervisor, the Research Associate designs the experimental approaches for various stages of an applied research project, directs research assistants and/or students, and communicates the results to the research supervisor, thus contributing to the success of research programs and/or projects. The focus of the position is applied research work related to molecular biology and genetics, including use of typical sequencing protocols and instruments (for PCR, qPCR, SNP- and SSR-based genotyping), and related bioinformatic methods. This may include working with single or multiple stakeholders, single or several project deliverables, and the use of instrumentation...LEARN MORE

Senior Director Medical Affairs

The Director, Medical Affairs will be responsible for defining and implementing KOL strategies to develop and maintain positive KOL endorsement and product champions for Eupraxia in OA diseases. The role will also be responsible for leading Eupraxia medical education initiatives and conference activities...LEARN MORE

Quality Control Supervisor – Deeley Research Centre, Victoria

The Quality Control Supervisor will support the manufacturing, quality control and quality assurance activities for the BCCA’s Cancer Immunotherapy Program, at the BCCA's Deeley Research Centre (DRC). The Quality Control Supervisor will provide supervision of the Quality Control group, ensuring efficient, orderly and seamless operation of the quality control laboratory at the CFIL including resource scheduling...LEARN MORE

Research Associate II, Protein Engineering

The role involves active participation in protein purification for multispecific antibodies to support research. Responsibilities include characterizing protein therapeutics, designing and executing experiments for screening antibody-based therapeutics, troubleshooting methods, and analyzing data. The candidate must maintain an organized lab, adhere to scientific standards and OH&S regulations, and actively foster collaborative relationships within the organization...LEARN MORE

Research Associate II – Protein Sciences

As a Research Associate II in Protein Sciences within the Integrated Sciences group, your key responsibilities include supporting protein activities, assisting the antibody generation team, documenting results, collaborating across teams, and managing program timelines to advance therapeutic efforts. Join our motivated drug discovery team, dedicated to delivering transformative medicines to patients while fostering an innovative and collaborative environment...LEARN MORE

Research Associate II – Antibody Generation

As a Research Associate II in the Antibody Generation group, you'll be responsible for optimizing antibody generation platforms, identifying lead antibody candidates, collaborating across teams, documenting results, presenting data, supporting innovative research strategies, and fostering a culture of innovation and collaboration. Join our dedicated drug discovery team with a focus on delivering transformative medicines to patients...LEARN MORE

Associate Scientist – Molecular Biology, Integrated Sciences

As an Associate Scientist in the Integrated Sciences group, your key responsibilities involve developing innovative assay solutions, providing support to the antibody generation team, improving core platforms, documenting results, collaborating across functions, managing program timelines, and fostering innovation. We seek candidates passionate about innovation and technical challenges to join our motivated drug discovery team dedicated to delivering transformative medicines while maintaining a culture of respect and trust...LEARN MORE

Senior Scientist, Formulation

NanoVation Therapeutics (NTx) is looking for an innovative and collaborative Senior Scientist, Formulation to join our team. Reporting to the CSO, the Senior Scientist, Formulation will work closely with the Formulation Team and will be responsible for designing and executing protocols related to internal and client-based projects, and subsequent data analysis. Our ideal candidate thrives on contributing collaboratively in a fast-paced, innovative environment and is open and interested in learning a variety of different research techniques...LEARN MORE

Scientist, Preclinical Development

This is a full-time Scientist role on the Preclinical Development team at Integrated Nanotherapeutics Inc. involving work across multiple sites: headquarters in Burnaby, BC, with in vivo research activities and flow cytometry conducted at sites in Vancouver, BC and flexibility for some remote work. The successful candidate will contribute to our R&D programs in antigen-specific immune tolerance by applying in vivo mouse and cellular immunology skills to develop and advance lead lipid nanoparticle-based products through preclinical pipelines...LEARN MORE

Biomanufacturing Trainer and Site Manager

Reporting to the Associate Director of Technical Training they will take a leadership role in overseeing the set-up and operations of the greater Vancouver Training Facility and supporting the company’s overall strategy. As an expert in the field of biopharmaceutical manufacturing and bioprocessing, the Biomanufacturing Trainer/Site Lead will work with the Associate Director of Technical Training and other company team members to deliver world-class in-person, virtual and practical hands-on training to a variety of learners...LEARN MORE

Associate I

The QC Associate is responsible for performing routine samples analysis in accordance with GMP and Evonik policies and practices. The QC Associate will also assist with equipment calibration/qualification and analytical method validation, as well as participating in quality system improvement initiatives. This is a lab-based position which will entail a high volume of testing in a regulated laboratory environment...LEARN MORE

Senior Manager, Site Engagement Lead

The role involves leading strategic partnerships with key clinical trial sites, ensuring collaboration and operational efficiency, and serving as a subject matter expert. The responsibilities include maintaining strong relationships with sites, sharing insights, resolving issues, and centralizing operational information to enhance clinical trial execution, while also collaborating with internal stakeholders and contributing to process improvements...LEARN MORE

Principal Scientist/Associate Director Biologics

Abdera Therapeutics is seeking a highly motivated and skilled leader in antibody discovery with a proven track record of antibody campaigns. This position will provide an exciting and dynamic opportunity to positively contribute to and lead research programs and teams developing next-generation targeted radiopharmaceutical therapies...LEARN MORE

Mitacs Post-Doc

A postdoctoral position is available in the laboratory of Prof. Filip Van Petegem at the University of British Columbia. The goal is to apply state of the art computational protein design methods to create novel protein molecules to enable structural cryo-EM characterization of therapeutic candidates and their target. The project is a collaboration with Amgen, one of the world’s leading biotechnology companies, and is supported through a MITACS scholarship...LEARN MORE

Piech Communications is a boutique agency that delivers results-focused PR and content for organizations, start-ups and researchers advancing the latest science. We translate complex ideas into compelling content, then strategically share this content so promising science can create long-lasting impacts. We specialize in content creation, strategic communications planning and implementation, media relations and crisis communications. We are proud to collaborate with organizations, start-ups and researchers who are working to improve lives — whether by advancing new therapeutic modalities, innovative approaches to drug discovery, or technologies that enhance health care delivery. Our areas of focus include life sciences, biotech and health research. LEARN MORE

Since 1960, Prudential Cleanroom Services (PCS) has provided cleanroom apparel services and has developed into an internationally recognized source for bioscience, USP compounding, pharmaceutical, medical device, semiconductor, aerospace, and other companies manufacturing and operating in controlled environments. PCS specializes in cleanroom garment processing services for aseptic, particulate & ESD controlled environments.

Prudential Cleanroom Services offers cleanroom solutions and services to facilities involved in the compounding and preparation of medications and sterile infusions. Utilizing PCS’s services with high quality sterile gowning and ancillary items required for cleanroom gowning and maintenance helps support a business’s cleanroom standards. LEARN MORE

Jevitty Life Science Corp is a Vancouver BC based company, with the mission of developing and delivering technologies for human longevity and healthspan.

The Bodycomp division of Jevitty (www.bodycomp.ca) provides dexa body composition scans at multiple locations in the Lower Mainland, as well as NeuroCatch brain health diagnostic scans.

Jevitty invests in and participates with various companies that are working on leading edge projects to further the objectives of living healthy and happy well beyond the current age expectancy.

Jevitty also has an interactive app that provides users with a useful dashboard for ongoing healthy activities, products and services, on both the IOS and Android platforms. LEARN MORE

NanoVation Therapeutics (NTx) is an early-stage gene therapy company developing next-generation platform technologies utilizing lipid nanoparticles for the safe and efficient delivery of nucleic acids to a variety of tissues.

With the emergence of gene therapies, we are at a crucial turning point in human history.

In our lifetimes, we will see major diseases become treatable or curable thanks to this new therapeutic approach.

Focused on translating personalized gene therapies to the clinic, NTx aims to treat and prevent multiple age-related diseases enabling a healthier tomorrow, TODAY. LEARN MORE

Stay current by subscribing to this and our events newsletter!

Follow LSBC on Social Media!